U.S. Markets close in 4 hrs 28 mins

Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018

Daniel Collins
Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018

Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.